Vertex Pharmaceuticals (VRTX) said on Oct. 20, 2026 that it appointed Daniel Brennan, a longtime healthcare finance executive and former chief financial officer of Boston Scientific, as an independent director. The board change is not a financial event, but it arrives while sales of the newer ALYFTREK are rising and TRIKAFTA/KAFTRIO sales are slightly lower. In the second quarter ended June 30, 2026, Vertex reported revenue of $3.33B and a net margin over the trailing 12 months of 34.9%.
Key facts
- Oct. 20, 2026: Vertex announced Daniel Brennan as an independent board member. According to its release, Brennan spent decades in finance roles at healthcare companies, most of them at Boston Scientific, and retired from the chief financial officer role there last year.
- Aug. 3, 2026: For the second quarter ended June 30, 2026, Vertex reported revenue of $3.33B against an analyst estimate of $3.23B, and EPS of 4.73 against an estimate of 4.74. The 4.73 figure is the basis analysts estimate against; it is not the GAAP figure (GAAP diluted EPS was 4.31, shown in the table below).
- June 30, 2026: Cash and short-term investments were $7.85B against total debt of $1.98B.
- Oct. 21, 2026: The shares were quoted at 524.52 USD, up 1.92% on the latest quote. The 52-week range is 403.16 to 560.25 USD.
- Nov. 2, 2026: Vertex's next earnings date. Analysts expect EPS of 4.8 and revenue of $3.41B.
Revenue grew 12.5% from a year earlier, and net income grew 6.5%.
What happened
The theme: large biotechs replacing their lead product. Many profitable biotech companies depend on one drug family. When patents age or a better version arrives, the company has to move patients to the successor before sales of the old product fade. Investors then watch two things: how fast the new product grows, and whether the company can keep its profit margins while it does so. Vertex is a clear example because TRIKAFTA/KAFTRIO and ALYFTREK together make up most of its revenue.
The latest development. Vertex added Brennan to its board as an independent director, meaning someone with no management role at the company. According to the release, Brennan's background is in finance at large healthcare companies, including financial oversight at a medical technology firm. The excerpt of the release we reviewed did not include a statement from Vertex on why it chose Brennan or which board committees Brennan will join. We are not drawing conclusions about the reasoning.
The business behind the board news. In the second quarter ended June 30, 2026, ALYFTREK revenue was $573.6M, well above the $156.8M a year earlier. TRIKAFTA/KAFTRIO revenue was $2.50B, slightly lower than the $2.55B a year earlier. In plain terms, sales of the newer ALYFTREK are rising while TRIKAFTA/KAFTRIO is slightly lower, and total revenue still rose. A third line, manufactured product and other revenue, was $137.1M, lower than the $236.1M a year earlier.
By region, the United States contributed $2.06B of revenue, and non-US sales were $1.58B, of which Europe was $977.7M.
Why it matters for investors
Margins slipped a little. Here is the five-quarter trend, oldest to newest:
| Quarter ended | Revenue | Gross margin | Operating margin | Net income | |---|---|---|---|---| | June 30, 2025 | $2.96B | 86.3% | 38.8% | $1.03B | | Sept. 30, 2025 | $3.08B | 86.5% | 38.6% | $1.08B | | Dec. 31, 2025 | $3.23B | 85.6% | 40.3% | $1.19B | | March 31, 2026 | $2.99B | 86.8% | 38.1% | $1.03B | | June 30, 2026 | $3.33B | 85.3% | 37.4% | $1.10B |
Revenue in the latest quarter was the highest of the five, but both gross margin (what is left after the direct cost of making the product) and operating margin (profit from running the business, before interest and taxes) were the lowest of the five. That means costs grew faster than sales. FMP data does not say why, and we did not have a call transcript to check against, so we cannot name management's stated reasons.
Cash generation stays strong but uneven. Free cash flow (cash from operations minus capital spending) was $1.01B in the latest quarter. The prior four quarters were $1.29B, $348.6M, $1.14B and $927.4M, going from the March 2026 quarter back to the June 2025 quarter. The $348.6M figure was for the quarter ended Dec. 31, 2025. Vertex pays no dividend. It spent $473.8M on share buybacks in the latest quarter, compared with $565.4M in the March 2026 quarter.
The balance sheet is conservative. Cash and short-term investments of $7.85B exceed total debt of $1.98B. Debt-to-equity is 0.10. The Altman Z score, a bankruptcy-risk gauge where higher is safer, is 13.39. The Piotroski score, a 0-to-9 gauge of financial health, is 5, which is middling.
Valuation versus peers. Vertex trades at a trailing P/E (price relative to the last 12 months of earnings) of 30.28, with price-to-sales of 10.53 and EV/EBITDA of 23.40. Among peers:
| Company | Market cap | P/E | Net margin | |---|---|---|---| | Vertex (VRTX) | $132.95B | 30.28 | 34.9% | | Alnylam (ALNY) | $30.12B | 36.90 | 16.8% | | BioMarin (BMRN) | $10.69B | 145.29 | 2.1% | | BridgeBio (BBIO) | $13.24B | -18.92 | -97.6% | | Beam Therapeutics (BEAM) | $2.57B | -30.29 | -54.7% |
A negative P/E means the company lost money over the period. Vertex is the most profitable in this group by net margin, and its P/E is lower than Alnylam's and BioMarin's.
What analysts think. Of 56 ratings, 47 are Buy, 8 are Hold and 1 is Sell, for a consensus of "Buy." Analyst price targets average 573.50 USD, with a median of 601.50 USD, a high of 665.00 USD and a low of 350.00 USD. Recent rating actions include RBC Capital maintaining Outperform on Oct. 8, 2026 and UBS maintaining Buy on Sept. 28, 2026. These are analysts' views, not ours.
Our MoonshotScore. Stock Expert AI's MoonshotScore V2 for Vertex is 97, labeled Exceptional. The pillars, measured against other companies in the sector, are growth 99, quality 96, safety 93, momentum 83 and valuation 43. Valuation is the weak pillar, which fits the premium the stock carries.
What could go wrong
- Concentration. TRIKAFTA/KAFTRIO and ALYFTREK together are the large majority of revenue. ALYFTREK growth has to continue for total growth to continue while TRIKAFTA/KAFTRIO is slightly lower.
- Margins. Gross and operating margins were the lowest of the last five quarters. If that continues, profit could trail revenue growth.
- Valuation. FMP's discounted cash flow model, which estimates what future cash flows are worth today, gives 317.71 USD per share as of Oct. 22, 2026. That is well below the 524.52 USD quote on Oct. 21. It is one model's estimate and depends heavily on its assumptions, but it shows the price already assumes continued growth.
- Earnings reaction risk. In August, EPS was one cent below the estimate while revenue beat it.
- Board news is small. A new director does not change the numbers by itself.
What to watch next
1. Nov. 2, 2026 earnings. Analysts expect EPS of 4.8 and revenue of $3.41B. Watch ALYFTREK revenue and whether TRIKAFTA/KAFTRIO revenue stays near the second-quarter level. 2. Margins. See whether margins stabilize: operating margin has fallen two quarters in a row, and gross margin in the latest quarter was the lowest of the five. 3. Free cash flow and buybacks. Check whether cash flow returns to the $1B-plus range and how much stock Vertex repurchases. 4. Board committee roles. Any disclosure of Brennan's committee assignments would show where the board expects to use that finance experience. 5. Longer-range estimates. Analysts expect revenue of $3.50B for the quarter ending March 30, 2028, within a range of $3.45B to $3.59B, based on 9 analysts.
Frequently asked questions
Q: Who is Daniel Brennan and why did Vertex appoint Brennan to the board?
According to Vertex's Oct. 20, 2026 release, Brennan is an independent director with decades of finance experience at healthcare companies, mostly at Boston Scientific, where Brennan was chief financial officer until retiring last year. The part of the release we reviewed did not explain the company's reasoning in detail.Q: Is Vertex stock expensive compared with other biotechs?
On trailing earnings, Vertex has a P/E of 30.28, lower than Alnylam at 36.90 and BioMarin at 145.29. Several other biotech peers, such as BridgeBio and Beam, have negative P/Es because they lose money. Our MoonshotScore valuation pillar is 43, which indicates a pricier profile relative to the sector, while its growth and quality pillars are 99 and 96. Whether that premium is justified depends on how well Vertex keeps growing.Q: How is Vertex's business doing right now?
In the second quarter ended June 30, 2026, revenue was $3.33B, higher than the $2.96B a year earlier, and net income was $1.10B. ALYFTREK revenue was $573.6M, far above $156.8M a year earlier, while TRIKAFTA/KAFTRIO revenue was $2.50B, slightly below $2.55B. Margins were the lowest of the last five quarters, which is the main thing to follow in the Nov. 2, 2026 report.This is educational content, not investment advice. Past performance does not guarantee future results.